Jiménez-Xarrié, Elena
Pérez, Belén
Dantas, Ana Paula
Puertas-Umbert, Lídia
Martí-Fabregas, Joan
Chamorro, Ángel
Planas, Anna Maria
Vila, Elisabet
Jiménez-Altayó, Francesc http://orcid.org/0000-0002-9034-2041
Funding for this research was provided by:
Ministerio de Ciencia e Innovación (SAF2014-56111-R)
Agència de Gestió d’Ajuts Universitaris i de Recerca (2017-SGR-645)
Instituto de Salud Carlos III (FIS PI13/0091, RIC RD12/0042/0006, RETICS-INVICTUS-RD16/019, RETICS-INVICTUS-RD16/019)
Article History
Received: 23 May 2018
Revised: 2 August 2018
Accepted: 30 August 2018
First Online: 15 September 2018
Compliance with Ethical Standards
:
: The authors declare that they have no conflict of interest.A.C. is inventor of the patent “Pharmaceutical composition for neuroprotective treatment in patients with ictus comprising citicoline and uric acid”.
: All institutional and national guidelines for the care and use of laboratory animals were followed. All of the experiments were carried out under the Guidelines established by the Spanish legislation (RD 1201/2005) and according to the <i>Guide for the Care and Use of Laboratory Animals</i>, published by the US National Institutes of Health (NIH Publication 85-23, revised 1996). Experiments were approved by the Ethics Committee of the Universitat Autònoma de Barcelona and were carried out in compliance with the European legislation.